Drugs / AG019
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03751007 | Oct 2018 → Oct 2021 | type 1 diabetes mellitus | Precigen Actobio T1D, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03751007 ↗ |
| Modality | Other / unclassified | “oral AG019, food-grade Lactococcus lactis bacteria genetically modified to express human proinsulin and human IL-10” PMID 37782353 ↗ Oct 2023 |
| Route | Oral | “Solid, orally administered capsule” NCT03751007 ↗ |